NovoCure (NASDAQ:NVCR) Shares Gap Up – Time to Buy?

NovoCure Limited (NASDAQ:NVCR)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $11.74, but opened at $12.56. NovoCure shares last traded at $14.2420, with a volume of 929,350 shares.

Trending Headlines about NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year?over?year — evidence of top?line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY?2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near?term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss?making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front?of?mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near?term issues), which could constrain margin improvement and near?term cash flow conversion. Article Title

Wall Street Analysts Forecast Growth

NVCR has been the subject of a number of analyst reports. Evercore set a $20.00 price target on NovoCure in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research note on Thursday, January 22nd. HC Wainwright lifted their price target on shares of NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wedbush reiterated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NovoCure presently has a consensus rating of “Hold” and an average price target of $26.93.

NovoCure Price Performance

The firm has a market capitalization of $1.53 billion, a P/E ratio of -8.49 and a beta of 0.73. The stock’s 50 day simple moving average is $12.71 and its 200 day simple moving average is $12.63. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.19. The firm had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative return on equity of 50.29% and a negative net margin of 27.66%.NovoCure’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.61) earnings per share. As a group, analysts expect that NovoCure Limited will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NovoCure

Several institutional investors have recently bought and sold shares of NVCR. Empowered Funds LLC purchased a new stake in NovoCure during the fourth quarter worth $33,000. SJS Investment Consulting Inc. bought a new position in shares of NovoCure in the 3rd quarter worth $41,000. Kestra Advisory Services LLC bought a new position in shares of NovoCure in the 4th quarter worth $49,000. Larson Financial Group LLC lifted its stake in shares of NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in NovoCure by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 1,120 shares in the last quarter. 84.61% of the stock is owned by hedge funds and other institutional investors.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.